Mr. Erinn Broshko reports
MED BIOGENE ANNOUNCES DATE OF ANNUAL AND SPECIAL MEETING
Med BioGene Inc. has provided the date of its upcoming annual and special meeting of shareholders.
Annual and special meeting
The meeting will be held on Tuesday, April 12, 2011, at 10 a.m. (Pacific Time) at the Terminal City Club, 837 West Hastings St., Vancouver, B.C.
At the meeting, shareholders will be asked to, among other things, approve the commercialization, licence and research reimbursement agreement with Precision Therapeutics Inc., as previously announced in Stockwatch on March 1, 2011. The agreement is subject to, among other things, the approval of MBI's shareholders and, upon the closing of all transactions contemplated in the agreement, MBI will grant to Precision exclusive worldwide rights to develop and commercialize LungExpress Dx.
The notice of meeting, information circular and form of proxy in respect of the meeting are being mailed to shareholders and will be available on SEDAR.